Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -27.68% | -34.36% | -39.91% | -25.77% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.68% | -34.36% | -39.91% | -25.77% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -27.68% | -34.36% | -39.91% | -25.77% | -- |
| SG&A Expenses | -15.77% | 0.74% | 20.18% | 20.51% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.77% | 11.99% | 17.62% | 15.45% | -- |
| Operating Income | -8.93% | -15.34% | -22.39% | -18.83% | -- |
| Income Before Tax | -8.57% | -16.20% | -24.72% | -23.02% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.57% | -16.20% | -24.72% | -23.02% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.57% | -16.20% | -24.72% | -23.02% | -- |
| EBIT | -8.93% | -15.34% | -22.39% | -18.83% | -- |
| EBITDA | -9.26% | -15.43% | -22.20% | -18.61% | -- |
| EPS Basic | 60.42% | 49.66% | 41.04% | 36.29% | -- |
| Normalized Basic EPS | 60.37% | 49.59% | 40.97% | 36.44% | -- |
| EPS Diluted | 60.42% | 49.66% | 41.04% | 36.29% | -- |
| Normalized Diluted EPS | 60.37% | 49.59% | 40.97% | 36.44% | -- |
| Average Basic Shares Outstanding | 196.15% | 166.90% | 126.97% | 106.61% | -- |
| Average Diluted Shares Outstanding | 196.15% | 166.90% | 126.97% | 106.61% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |